TY - JOUR
T1 - Mindfulness-based cognitive therapy in advanced prostate cancer
T2 - A randomized controlled trial
AU - Chambers, Suzanne K.
AU - Occhipinti, Stefano
AU - Foley, Elizabeth
AU - Clutton, Samantha
AU - Legg, Melissa
AU - Berry, Martin
AU - Stockler, Martin R.
AU - Frydenberg, Mark
AU - Gardiner, Robert A.
AU - Lepore, Stephen J.
AU - Davis, Ian D.
AU - Smith, David P.
N1 - Funding Information:
Supported by an Australian National Health and Medical Research grant (APP1024989). S.K.C. is an Australian Research Council Future Fellow. I.D.D. is a National Health and Medical Research Council Practitioner Fellow. Astellas Pharma (Inst), Celgene (Inst), Bayer AG (Inst), Bionomics (Inst), Medivation (Inst), Sanofi (Inst), Pfizer (Inst), AstraZeneca (Inst), Bristol-Myers Squibb (Inst) Astellas Pharma (Inst), Exelixis (Inst) This project was a collaboration among Griffith University, the Cancer Council Queensland, and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). We gratefully acknowledge the support of the Prostate Cancer Foundation of Australia and the Urological Society of Australia and New Zealand, of Robert McDowall who was project manager of the trial, of the medical centers that recruited for this trial (Austin Health, Australian Urology Associates, Bankstown Private Practice, Brisbane Urology Clinic, Concord General Repatriation Hospital, Eastern Health, Flinders Medical Centre, Fremantle Hospital, Genisis CancerCare QLD, Greenslopes Hospital, Highfields Specialist Centre Port Macquarie, John Flynn Hospital, Liverpool Hospital, Lyell-McEwin Hospital, Nepean Hospital, Northern Cancer Institute, Prince of Wales Hospital, Princess Alexandra Hospital, Radiation Oncology Mater Centre, Redcliffe Hospital, Repatriation General Hospital, Royal Brisbane and Women's Hospital, Royal Prince Alfred Hospital, Sir Charles Gairdner Hospital, St John of God Hospital, Sydney Adventist Hospital, Townsville Urology, Westmead Hospital, Westmead Private, Whyalla Hospital, and Yaxley Urology), and of the men who participated in this project. The Australian and New Zealand Urogenital and Prostate Cancer Trials Group is supported by funding through Cancer Australia and Cancer Institute New South Wales.
Publisher Copyright:
© 2016 by American Society of Clinical Oncology.
PY - 2017/1/20
Y1 - 2017/1/20
N2 - Purpose: Advanced prostate cancer (PC) is associated with substantial psychosocial morbidity. We sought to determine whether mindfulness-based cognitive therapy (MBCT) reduces distress in men with advanced PC. Methods: Men with advanced PC (proven metastatic and/or castration-resistant biochemical progression) were randomly assigned to an 8-week, group-based MBCT intervention delivered by telephone (n = 94) or to minimally enhanced usual care (n = 95). Primary intervention outcomes were psychological distress, cancer-specific distress, and prostate-specific antigen anxiety. Mindfulness skills were assessed as potential mediators of effect. Participants were assessed at baseline and were followed up at 3, 6, and 9 months. Main statistical analyses were conducted on the basis of intention to treat. Results: Fourteen MBCT groups were conducted in the intervention arm. Facilitator adherence ratings were high (> 93%). Using random-effects mixed-regression models, intention-to-treat analyses indicated no significant changes in intervention outcomes or in engagement with mindfulness for men in MBCT compared with those receiving minimally enhanced usual care. Per-protocol analyses also found no differences between arms in outcomes or engagement, with the exception of the mindfulness skill of observing, which increased over time for men in MBCT compared with usual care (P = .032). Conclusion: MBCT in this format was not more effective than minimally enhanced usual care in reducing distress in men with advanced PC. Future intervention research for these men should consider approaches that map more closely to masculinity.
AB - Purpose: Advanced prostate cancer (PC) is associated with substantial psychosocial morbidity. We sought to determine whether mindfulness-based cognitive therapy (MBCT) reduces distress in men with advanced PC. Methods: Men with advanced PC (proven metastatic and/or castration-resistant biochemical progression) were randomly assigned to an 8-week, group-based MBCT intervention delivered by telephone (n = 94) or to minimally enhanced usual care (n = 95). Primary intervention outcomes were psychological distress, cancer-specific distress, and prostate-specific antigen anxiety. Mindfulness skills were assessed as potential mediators of effect. Participants were assessed at baseline and were followed up at 3, 6, and 9 months. Main statistical analyses were conducted on the basis of intention to treat. Results: Fourteen MBCT groups were conducted in the intervention arm. Facilitator adherence ratings were high (> 93%). Using random-effects mixed-regression models, intention-to-treat analyses indicated no significant changes in intervention outcomes or in engagement with mindfulness for men in MBCT compared with those receiving minimally enhanced usual care. Per-protocol analyses also found no differences between arms in outcomes or engagement, with the exception of the mindfulness skill of observing, which increased over time for men in MBCT compared with usual care (P = .032). Conclusion: MBCT in this format was not more effective than minimally enhanced usual care in reducing distress in men with advanced PC. Future intervention research for these men should consider approaches that map more closely to masculinity.
UR - http://www.scopus.com/inward/record.url?scp=85010075912&partnerID=8YFLogxK
U2 - 10.1200/JCO.2016.68.8788
DO - 10.1200/JCO.2016.68.8788
M3 - Journal article
C2 - 27870567
AN - SCOPUS:85010075912
SN - 0732-183X
VL - 35
SP - 291
EP - 297
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 3
ER -